This has led to clinical trials studying PD-1 (pembrolizumab/nivolumab) [29,30] and PD-L1 inhibitors (atezolizumab [31] and durvalumab [32]) in patients with cutaneous T-cell lymphoma. The gene discussed is CD274; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.